Evidence map›Paper›PMID 29610119›Full record

ArticleClinical medicine & research2018

Biologic Agent-Associated Cutaneous Adverse Events: A Single Center Experience.

Rahul Sehgal, Erik J Stratman, Jonathan E Cutlan

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical medicine & research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Focus on Anti-Tumour Necrosis Factor (TNF)-α-Related Autoimmune Diseases.International journal of molecular sciences · 2023
    Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Rahul SehgalMayo Clinic Health System, Department of Rheumatology, Eau Claire, WI 54702 USA Sehgal.rahul@mayo.edu.
Erik J StratmanMarshfield Clinic Health System, Department of Dermatology, Marshfield, WI 54449 USA.
Jonathan E CutlanMarshfield Clinic Health System, Department of Pathology, Marshfield, WI 54449 USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Biologic agents are regarded as an effective treatment for a variety of autoimmune diseases. These drugs have an acceptable safety and tolerability profile, although an increasing number of autoimmune conditions have been reported with their use. Additionally, a variety of cutaneous diseases have been associated with their use. Here we report our experience of adverse cutaneous events with the use of biologic agents. An alternative explanation for patients presenting with adverse cutaneous events including drug interactions must be carefully investigated.

Indexed as

AdultAgedAntibodies, Monoclonal, HumanizedAntirheumatic AgentsArthritis, PsoriaticArthritis, RheumatoidCertolizumab PegolErythemaEtanerceptFemaleHumansMaleMiddle AgedNeutrophilsPsoriasisTakayasu ArteritisAntibodies, Monoclonal, HumanizedAntirheumatic AgentsCertolizumab PegolEtanercepttocilizumabAdverse drug eventsAnti-TNF therapyAutoimmune diseaseBiologic agentsCutaneous vasculitis

Identifiers

PMID29610119
PMCPMC6108513

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.